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Abstract
Penetrance, which plays a key role in genetic research, is defined as the propor-
tion of individuals with the genetic variants (i.e., genotype) that cause a particular
trait and who have clinical symptoms of the trait (i.e., phenotype). We propose a
Bayesian semiparametric approach to estimate the cancer-specific age-at-onset pene-
trance in the presence of the competing risk of multiple cancers. We employ a Bayesian
semiparametric competing risk model to model the duration until individuals in a high-
risk group develop different cancers, and accommodate family data using family-wise
likelihoods. We tackle the ascertainment bias arising when family data are collected
through probands in a high-risk population in which disease cases are more likely to be
observed. We apply the proposed method to a cohort of 186 families with Li-Fraumeni
syndrome identified through probands with sarcoma treated at MD Anderson Cancer
Center from 1944 to 1982.
Keyword: cancer specific age-at-onset penetrance, competing risk, gamma frailty model,
family-wise likelihood, Li-Fraumeni syndrome
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1 Introduction
The Li-Fraumeni syndrome (LFS) is a rare disorder that substantially increases the risk of
developing several cancer types, particularly in children and young adults. It is characterized
by autosomal dominant mutation inheritance with frequent occurrence of several cancer
types: soft tissue/bone sarcoma, breast cancer, lung cancer, and other types of cancer that
are grouped together as “other cancers” (Nichols et al.; 2001; Birch et al.; 2001). A majority
of LFS is caused by germline mutations in the TP53 tumor suppressor gene (Malkin et al.;
1990; Srivastava et al.; 1990).
The LFS data that motivate our work are family data collected through patients diag-
nosed with pediatric sarcoma (i.e., probands) who were treated at MD Anderson Cancer
Center from 1944 to 1982 and their extended kindred. The data consist of 186 families, with
a total of 3686 subjects. The size of the families ranges from 3 to 717, with the median at
7. This dataset is the longest followed-up cohort in the world (followed up for 20-50 years),
and among the largest collection of TP53 mutation carriers in all cohorts that are available
for LFS. Considering the prevalence of TP53 mutations in a general population is as low
as 0.0001 to 0.003, this dataset provides a specially enriched collection of TP53 mutations,
which then allow us to characterize its effect on a diverse cancer outcomes. For each subject,
the duration until he/she develops cancer is recorded as the primary endpoint. Although
it is possible for LFS patients to experience multiple cancers during their lifetime, here, we
focus on only the time to the first primary cancer since only a few patients represented in the
database experienced multiple primary cancers. Table 1 shows the cancer-specific summaries
for the LFS data. Further descriptions of the data are provided by Lustbader et al. (1992),
Strong et al. (1992), and Hwang et al. (2003).
The primary objective here is to estimate the cancer-specific age-at-onset penetrance as
a measure of the risk of experiencing a specific cancer for a person with a specific genotype
(i.e., TP53 mutation status). Penetrance, which plays a crucial role in genetic research,
is defined as the proportion of individuals with the genetic variants (i.e., genotype) that
cause a particular trait who also have clinical symptoms of the trait (i.e., phenotype). When
the clinical traits of interest are age-dependent (e.g., cancers), it is often more desirable to
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estimate the age-at-onset penetrance, defined as the probability of disease onset by a certain
age, while adjusting for additional covariates if necessary. For the LFS study, the age-at-
onset penetrance is defined as the conditional probability of having LFS-related cancers by
a certain age given a certain TP53 mutation status. Cox proportional hazard regression
models (Gauderman and Faucett; 1997; Wu et al.; 2010, among many others) have been
most widely used for this task. Other approaches have included nonparametric estimation
Wang et al. (2007) and parametric estimation based on logistic regression (Abel et al.; 1990)
or a Weibull model (Hashemian et al.; 2009).
Estimating the age-at-onset penetrance for the LFS data is challenging for several reasons.
First, LFS involves multiple types of cancer, and subjects have simultaneous competing
risks of developing multiple types of cancer. Chatterjee et al. (2003) proposed a penetrance
estimation method under a competing risk framework for a kin-cohort design. However,
their method is not directly applicable if the pedigree size is large and/or there is additional
genetic information from relatives. Gorfine and Hsu (2011) and Gorfine et al. (2014) proposed
frailty-based competing risk models for family data, assuming that genotypes are completely
observed for all family members, which is not the case for the LFS data.
Second, the genotype (i.e., TP53 mutation status) is not measured for the majority (about
74%) of subjects and the LFS data are clustered in the form of families. Accommodating
the missing data and accounting for family or pedigree data structure are statistically and
computationally challenging. As shown later, to efficiently utilize the observed genotype
data nested in the family structure, we need to marginalize the likelihood over (or integrate
Table 1: Frequency table for LFS data.
Gender Genotype Breast Sarcoma Others Censored Total
Unknown 0 11 130 1275 1416
Male Wildtype 0 76 30 295 401
Mutation 0 12 27 9 48
Subtotal 0 99 187 1579 1865
Unknown 39 4 62 1204 1309
Female Wildtype 8 96 17 343 464
Mutation 19 12 7 10 48
Subtotal 66 112 86 1557 1821
Total 66 211 273 3136 3686
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out) all possible genotypes for subjects with missing genotype information, and meanwhile
take into account the available genotypes in the family under the given pedigree structure.
Third, the LFS data are not a random sample, but have been collected through probands
diagnosed with sarcoma at young ages. That is, the data oversampled sarcoma patients.
Such a sampling scheme inevitably creates bias, known as ascertainment bias, and should be
properly adjusted to obtain unbiased results. Several likelihood-calibrated models have been
developed to correct the ascertainment bias, including the retrospective model (Kraft and
Thomas; 2000), the conditional-on-ascertainment variable model (Ewens and Shute; 1986;
Pfeiffer et al.; 2001), and the ascertainment-corrected joint model (Kraft and Thomas; 2000;
Iversen and Chen; 2005), among others.
To address these challenges, in this article, we develop a Bayesian semiparametric ap-
proach to estimate the cancer-specific age-at-onset penetrance in the presence of the compet-
ing risks of developing multiple cancers. We employ a Bayesian semiparametric competing
risk model to model the time to different types of cancer and introduce the family-wise
likelihood to minimize information loss from missing genotypes and harness the information
contained in the pedigree structure. We employ the peeling algorithm (Elston and Stewart;
1971) to evaluate the family-wise likelihood, and utilize the ascertainment-corrected joint
model (Kraft and Thomas, 2000) to correct the ascertainment bias.
The rest of the article is organized as follows. In Section 2, we define the cancer-specific
age-at-onset penetrance and describe our Bayesian semiparametric competing risk model
including details about the family-wise likelihood and the ascertainment bias correction. In
Section 3, we provide an algorithm to fit the models and carry out a simulation study in
Section 4. We apply the proposed methodology to the LFS data in Section 5. Discussions
follow in Section 6.
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2 Model
2.1 Cancer-specific Age-at-onset Penetrance
Let G denote a subject’s genotype, and X denote the baseline covariates (e.g., gender).
Suppose that K types of cancer are under consideration and compete against each other
such that the occurrence of one type of cancer censors the other types of cancer. Let Tk
denote the time to the kth type of cancer, k = 1, . . . , K, and define T = mink∈{1,··· ,K} Tk
and Y = min{T,C}, where C is a conditional random censoring time given G and X, i.e.,
T⊥C|G,X. Let D denote the cancer type indicator, with D = k if T = Tk < C (i.e., the
kth type of cancer that occurs); otherwise, D = 0 (i.e., censored observation). The actual
observed time-to-event data are H = (Y,D).
Traditionally, when analyzing subjects at risk of developing a single disease, the age-
at-onset penetrance is defined as the probability of having the disease at a certain age
given a certain genotype. In order to study LFS, where subjects simultaneously have the
(competing) risk of developing multiple types of cancer, this standard definition must be
extended. Borrowing ideas from the competing risk literature, we define the kth cancer-
specific age-at-onset penetrance, denoted by qk(t|G,X), as the probability of having the kth
type of cancer at age t prior to developing other cancers (competing risks), given a specific
genotype G and additional baseline covariates X if necessary, that is,
qk(t|G,X) = Pr(T ≤ t,D = k|G,X), k = 1, · · · , K. (1)
The cancer-specific penetrance qk(t|G,X) can be estimated as
qk(t|G,X) =
∫ t
0
λk(u|G,X)S(u|G,X)du, k = 1, · · · , K, (2)
where
λk(t|G,X) = lim
h↓0
Pr(t ≤ T < t+ h,D = k|T > t,G,X)
h
, (3)
and
S(t|G,X) = exp
{
−
K∑
k=1
Λk(t|G,X)
}
,
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with Λk(t|G,X) =
∫ t
0
λk(u|G,X)du. In the competing risk literature, λk(t|G,X) and Λk(t|G,X)
are referred to as the cancer-specific hazard and cancer-specific cumulative hazard, respec-
tively. We note that it may be tempting to define the cancer-specific age-at-onset penetrance
function as Pr(Tk ≤ t|G,X), which is analogous to the conventional definition of penetrance
for a single disease. However, that quantity is not identifiable in nonparametric models
(Tsiatis; 1975).
Besides cancer-specific penetrance, it is often of practical interest to estimate the overall
age-at-onset penetrance, defined as
q(t|G,X) = Pr(T ≤ t|G,X), (4)
which is the probability that a subject has any type of cancer by age t given his/her geno-
type G and baseline characteristics X, and can be calculated through the cancer-specific
penetrance qk(t|G, x) using q(t|G,X) =
∑K
k=1 qk(t|G,X).
2.2 Competing Risk Model
In the rest of the article, without loss of generality, we focus on the LFS data where X
denotes gender coded as 1 for the male and 0 for the female, and G denotes TP53 mutation
status. As LFS is autosomal dominant, let G = 1 denote genotype Aa or AA, and G = 0
denote genotype aa, where A and a denote the (minor) mutated and wildtype alleles in the
TP53 tumor suppressor gene, respectively. Let Z = (G,X,G ×X)T , with G ×X denoting
the interaction between G and X. We model the hazard for the kth type of cancer, say
λk(t|Z, ξi,k), using a frailty model as follows:
λk(t|Z, ξi,k) = λ0,k(t)ξi,k exp{βTkZ}, k = 1, · · · , K, (5)
where βk denotes the regression coefficient parameter vector; λ0,k(t) is a baseline hazard
function; and ξi,k is the ith family-specific frailty (or random effect) used to account for the
within-family correlation induced by non-genetic factors that are not included in X. The
pedigree information (or genetic relationship) within a family will be incorporated through
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the family-wise likelihood described in Section 2.3. We assume that ξi,k follows a gamma
distribution, ξ1,k, · · · , ξI,k ∼ Gamma(νk, νk). Such a gamma frailty has been widely used in
frailty models (Duchateau and Janssen; 2007).
Under this model, the cancer-specific age-at-onset penetrance can be expressed as
qk(t|Z) =
∫ t
0
∫
ξ∈[0,∞)K
λk(u|Z, ξk)S(u|Z, ξ)f(ξ|ν)dξdu
=
∫ t
0
νk
(νk − log{S∗k(u|Z)})
λ0,k(u) exp{βTkZ}S(u|Z)du, (6)
where S∗k(t|Z) = exp
{
− ∫ t
0
λk,0(u) exp{βTkZ}du
}
and S(t|Z) = ∏Kk=1 Sk(t|Z) with
Sk(t|Z) =
∫ ∞
0
exp
{
−
∫ t
0
λk(u|Z, ξk)du
}
f(ξk|νk)dξk
=
[
νk
νk − log{S∗k(t|Z)}
]νk
.
Because the penetrance depends on the survival function, it is imperative to specify
the baseline hazard λ0,k(t), which appears in (5). To this end, we propose to approximate
the cumulative baseline hazard Λ0,k(t) =
∫ t
0
λ0,k(s)ds via Bernstein polynomials (Lorentz;
1953) since Λ0,k(t) is monotone increasing. Bernstein polynomials are popular in Bayesian
nonparametric function estimation, with shape restrictions due to desired properties such
as the optimal shape restriction property (Carnicer and Pen˜a; 1993) and the convergence
property of their derivatives (Lorentz; 1953). Without loss of generality, we assume t has
been rescaled, e.g., by the largest observed time, such that t ∈ [0, 1]. Now, we have Λ0,k(t)
approximated by Bernstein polynomials of degree M as follows (Chang et al.; 2005).
Λ0,k(t) ≈
M∑
l=1
ωl,k
(
M
l
)
tl(1− t)M−l, (7)
where ωl,k = Λ0,k(l/M) and ω1,k ≤ · · · ≤ ωM,k to ensure that Λ0,k(t) is monotone increasing.
Notice that l is running from 1 because of Λ0,k(0) = 0. Applying the re-parameterization of
γl,k = ωl,k − ωl−1,k with ω0,k = 0 and γl,k ≥ 0, l = 1, · · · ,M , the right-hand side of (7) can
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be equivalently rewritten as
M∑
m=1
γm,k
∫ t
0
um(1− u)M −m
Beta(m,M −m+ 1)du = γ
T
kBM(t), (8)
where BM(t) = (BM(t, 1), · · · , BM(t,M))T , with BM(t,m) being the distribution function
of the beta distribution evaluated at the value of t with parameters m and M −m+ 1, and
γk = (γ1,k, · · · , γM,k)T (Curtis and Ghosh; 2011). Therefore, it follows that
λ0,k(t) ≈ γTkbM(t), (9)
where bM(t) = (bM(t, 1), · · · , bM(t,M))T and bM(t,m) = ∂BM(t,m)/∂t (i.e., associated beta
density). Finally, the frailty model (5) can be written as
λk(t|Z;βk,γk, ξi,k) = {γTkbM(t)}ξi,k exp{βTkZ}. (10)
The proposed nonparametric baseline hazard model (9) is more flexible than parametric
models, such as exponential and Weibull models, without imposing a restrictive parametric
structure on the shape of the baseline hazard. Compared to the piecewise constant hazard
model, our approach produces a smooth estimate of hazard and also avoids selection of knots,
which is often subjective. The numerical comparison of different baseline models is provided
in Section 5.5 and Supplementary Materials Section C.
2.3 Family-wise Likelihood
Let i index the family and j index the individual within the family, where i = 1, · · · , I,
and j = 1, · · · , ni. For the ith family, let Hi = (Hi1, · · · , Hini) with Hij = (Yij, Dij) and
Xi = (Xi1, · · · , Xini). Let Gi,obs and Gi,mis respectively denote the observed and missing
parts of genotype data Gi = (Gi1, · · · , Gini), i.e., Gi = (Gi,obs,Gi,mis) if we ignore the order
of the elements for simplicity. Conditional on frailty ξi = (ξi,1, · · · , ξi,K), the likelihood of Hi
for the ith family is Pr(Hi|Gi,obs,Xi,θ, ξi) which we call the family-wise likelihood, where
θ = {(βTk ,γTk ) : k = 1, · · · , K} denotes a vector of model parameters except the frailty.
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Evaluation of the family-wise likelihood Pr(Hi|Gi,obs,Xi,θ, ξi) is not trivial because the
individual disease histories Hi1, · · · , Hini are not conditionally independent given Gi,obs and
ξi, due to the dependency through Gi,mis. Note that Hi1, · · · , Hini will be conditionally
independent when conditional on complete genotype data Gi and ξi. In this article, we
use Elston-Stewart’s peeling algorithm (Elston and Stewart; 1971; Lange and Elston; 1975;
Fernando et al.; 1993) to compute the family-wise likelihood, described as follows. We assume
that there is no loop in the pedigree, which is generally true in practice, and suppress the
family subscript i and the conditional arguments except Gobs for notational brevity.
A pedigree without loop can be partitioned into two disjoint groups, known as anterior
and posterior, that are connected only through an arbitrary pivot member, say j. The
anterior are the member in the pedigree who are connected to the pivot member through
his/her parents, and the posterior are the member in the pedigree who are connected to
the pivot member through his/her spouse and offsprings, see Figure 1 for an example. In
our implementation, we use the proband as the pivot member of each family. Let H−j ,
and H+j denote the phenotypes of anterior and posterior, respectively. We partition H =
(H−j , Hj,H
+
j ). Because anterior and posterior are connected only through the pivot member
j, H−j and H
+
j are conditionally independent given pivot member’s genotype Gj.
If Gj is unobserved, the family-wise likelihood P (H|Gobs) can be written as
Pr(H|Gobs) =
∑
Gj
{
Pr(Gj|Gobs) Pr(H−j , Hj,H+j |Gj,Gobs)
}
=
∑
Gj
{
Pr(Gj|Gobs) Pr(H−j |Gj,Gobs) Pr(Hj|Gj,Gobs) Pr(H+j |Gj,Gobs)
}
=
∑
Gj
{
Aj(Gj|Gobs) Pr(Hj|Gj)Pj(Gj|Gobs)
}
, (11)
where
(Anterior probability of j) Aj(Gj|Gobs) = Pr(H−j , Gj|Gobs),
(Posterior probability of j) Pj(Gj|Gobs) = Pr(H+j |Gj,Gobs),
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and the individual likelihood Pr(Hj|Gj) is computed from the proposed model as
Pr(Hj|Gj) := Pr(Hij|Gij, Xij,θ, ξi) ∝
K∏
k=1
{λk(Yij|Zij,θ, ξi)}∆ijk exp {−Λk(Yij|Zij,θ, ξ)} ,
with ∆ijk = 1 if Dij = k and 0 otherwise (Prentice et al.; 1978; Maller and Zhou; 2002).
In the case that Gj is observed, the summation in (11) is not needed and the family-wise
likelihood is reduced to
Pr(H|Gobs) = Aj(Gj|Gobs) Pr(Hj|Gj)Pj(Gj|Gobs). (12)
To calculate Aj(Gj|Gobs) and Pj(Gj|Gobs), H−j and H+j can be further partitioned into
anterior and posterior in a similar way as above. Thus, the family-wise likelihood Pr(H|Gobs)
can be evaluated in a recursive way. An illustrative example of using the peeling algorithm
to evaluate the family-wise likelihood is provided in Supplementary Materials Section A.
Fernando et al. (1993) provides the details on the recursive formulation of the algorithm.
2.4 Ascertainment Bias Correction
For studies of rare diseases, such as LFS, ascertainment bias is inevitable when family data
are collected through probands in high-risk populations in which disease cases are more likely
to be observed. In order to correct the ascertainment bias, we employ the ascertainment-
corrected joint (ACJ) likelihood (Kraft and Thomas; 2000; Iversen and Chen; 2005). In
particular, we closely follow the approach proposed by Iversen and Chen (2005). Let Ai
denote the ascertainment indicator variable, such that Ai = 1 if the ith family is ascertained
and 0 otherwise. In the LFS data, a family is ascertained and included in the sample only if
the proband is diagnosed with sarcoma. Following the idea of Iversen and Chen (2005), the
ACJ likelihood for the LFS data is given by
Pr(Hi,Gi,obs|Xi,θ, ξi,Ai = 1)
=
Pr(Ai = 1|Hi,Gi,obs,Xi,θ, ξi) Pr(Hi|Gi,obs,Xi,θ, ξi) Pr(Gi,obs|Xi,θ, ξi)
Pr(Ai = 1|Xi,θ, ξi)
. (13)
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Because the ascertainment decision is made on the basis of Hi1 (i.e., phenotype of the
proband) in a deterministic way, the first term in the numerator of equation (13), i.e.,
Pr(Ai = 1|Hi,Gi,obs,Xi,θ, ξi), is independent of the model parameters θ and ξi. In addition,
the third term in the numerator of equation (13), i.e., Pr(Gi,obs|Xi,θ, ξi) is also independent
of both θ and ξi, the parameters of the penetrance model. As a result, we have
Pr(Hi,Gi,obs,Xi|θ, ξi,Ai = 1) ∝
Pr(Hi|Xi,Gi,obs,θ, ξi)
Pr(Ai = 1|Xi,θ, ξi)
. (14)
This means that the ascertainment bias can be corrected by inverse-probability weighting
the likelihood by the corresponding ascertainment probability, which is given by
Pr(Ai = 1|Xi,θ, ξi) =
∑
Hi1
Pr(Ai = 1|Hi1)Pr(Hi1|Xi1,θ, ξi). (15)
In the LFS data, a family is ascertained only if the proband is diagnosed with sarcoma (coded
as D = 2). We assume that the sarcoma patients visiting MD Anderson Cancer Center are
not be very different from the ones visiting other clinics, then it follows
Pr(Ai = 1|Yi1, Di1 = 2) = 1 and Pr(Ai = 1|Yi1, Di1 6= 2) = 0.
The assumption is empirically acceptable in our application, and partially validated in Sec-
tion 5.4 by comparing our estimates for non-carriers to those from the US population. In
general, however, the assumption may not be valid, then we cannot generalize our results to
the US population, but to the patients visiting MD Anderson Cancer Center only.
11
Recalling Hi1 = (Yi1, Di1), the ascertainment probability (15) is given by
Pr(Ai = 1|Xi,θ, ξi) = Pr(Yi1, Di1 = 2|Xi1,θ, ξi)
=
∑
G
Pr(Yi1, Di1 = 2|G,Xi1,θ, ξi)Pr(G|Xi1)
=
∑
G
[
λ2(Yi1|G,Xi1, G×Xi1,β2,γ2, ξi,2)
× exp
{
−
K∑
k=1
Λk(Yi1|G,Xi1, G×Xi1,βk,γk, ξi,k)
}
Pr(G|Xi1)
]
.
(16)
The gender-specific prevalence Pr(G|Xi1) is often assumed to be gvien when estimating the
penetrance (Iversen and Chen; 2005). In our application, the TP53 mutation prevalence is
independent of gender i.e., Pr(G|X) = Pr(G), and it can be calculated on the basis of the
mutated allele frequency φA, i.e., Pr(G = 0) = (1 − φA)2 and Pr(G = 1) = 1 − (1 − φA)2.
The prevalence of a germline TP53 mutation in the Western population is known to be
φA = 0.0006 (Lalloo et al.; 2003).
As shown above, the key is that we assume that the mutated allele frequency φA is
known or can be reliably estimated from external data sources. Given a known mutated
allele frequency φA, the frequency of each genotype G can be determined using the Mendelian
laws of inheritance. Thus, coupling with the penetrance model, the sampling probability can
be estimated, e.g., equation (16), and used to inversely weight the observed data likelihood
to make inference for the target population. For many genetic studies, it is often reasonable
to assume that the mutated allele frequency φA is known or can be reliably estimated from
external data sources.
The ACJ likelihood of the entire data of I mutually independent families is given by the
product of (14)
Pr(H,Gobs|X,θ, ξ,A) ∝
I∏
i=1
Pr(Hi|Gi,obs,Xi,θ, ξi)
Pr(Ai = 1|θ, ξi)
,
where H = (Hi, · · · ,HI), Gobs = (G1,obs, · · · ,GI,obs) and A = (A1, · · · ,AI).
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3 Prior and Posterior Sampling
We use an independent normal prior for βk, i.e., βk ∼ N(0, σ2I), where 0 and I denote a zero
vector and an identity matrix, respectively, and we set a large value of σ for vague priors.
For the nonnegative parameter γm,k,m = 1, · · · ,M, k = 1, · · · , K for the baseline hazard,
we use the noninformative flat prior. We assign νk, k = 1, · · · , K, the independent vague
gamma prior Gamma(0.01, 0.01). See Section 5.6 for the results of the sensitivity analysis of
γm,k and νk. For the choice of M , a large value provides more flexibility to model the shape
of the baseline hazard, but at the cost of increasing the computational burden. Gelfand and
Mallick (1995) suggest that a small value of M works well for most applications. We set
M = 5 in the analysis.
Let Pr(θ) and Pr(ν) denote the prior distributions of θ and ν, respectively. The joint
posterior distribution of ν, ξ and θ is given by
Pr(θ, ξ,ν|H,Gobs,X,A) ∝ Pr(H,Gobs|X,θ, ξ,A) · Pr(θ) · Pr(ξ|ν) · Pr(ν).
We employ the random walk Metropolis-Hastings algorithm within Gibbs sampler to
sample the posterior distribution. We generate 100,000 posterior samples in total and take
every fifth sample for thinning after discarding the first 10,000 samples for burn-in. We
implement the Markov chain Monte Carlo (MCMC) algorithm in R, which takes about three
seconds per single MCMC iteration. We observe that the physical computing time is ap-
proximately linear, corresponding to the number of families, I, regardless of the family size
ni.
4 Simulation
We conduct a simulation study to evaluate the performance of the proposed method. Suppose
that there are two competing cancers, indicated by D = 1 and 2, respectively. We simulate
200 families of three generations with 30 members (see Figure 1) that are collected through
probands indexed by {1} in Figure 1 with the second type of cancers (i.e., D = 2), as follows:
1. We first simulate a genotype G ∼ Bernoulli(0.0001) for the proband. Given G, we then
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simulate his/her true time to cancer, Tk, k = 1, 2, from the following cancer-specific
frailty model:
λk(t|G) = λ0,k(t)ξk exp(βkG), k = 1, 2, (17)
with β1 = 4, β2 = 10, λ0,1(t) = 0.1, λ0,2(t) = 0.0005, and ξ1, ξ2
iid∼ Gamma(0.25, 0.25).
We choose these simulation parameters such that the second type of cancer (i.e., D = 2)
is rare with the prevalence of about 0.0003, while that of the first type of cancer is
about 0.05. Random censoring time C is simulated from Exponential(2). To mimic
the ascertainment process of the LFS data, only probands with D = 2 are selected
and included in the sample as probands. We repeat the above procedure until 200
probands are collected.
2. Given probands’ data, we generate genotypes of their family members as follows. If
proband {1} is a non-carrier (G = 0), all family members are set as non-carriers; other-
wise, we randomly select one of proband’s parents {3, 4} as a carrier and set the another
as a non-carrier. Offsprings and siblings of the proband, including {7, 8, 9, 10, 11, 12},
are set as carriers with probability 0.5. If {11} is carrier, his offsprings, including
{19, 20, 21}, are set as carries with probability 0.5, otherwise set as noncarriers. Geno-
Figure 1: Pedigree of the simulated family of three generations with 30 members.
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types of {22, 23, 24} are generated similarly based on the genotype of their mother {12}.
Assuming that the mutation is extremely rare, the family members who are not geneti-
cally related with the proband, including {2, 5, 6, 13, 14, 15, 16, 17, 18, 25, 26, 27, 28, 29, 30},
are set as non-carriers.
3. Given the genotypes, the time to cancer of the family members are generated from
model (17).
4. Lastly, we randomly delete genotypes for a half of subjects who are not a proband.
We set M = 3 for the Bernstein model for the baseline hazard functions, λ0,k(t), k = 1, 2.
For estimation, we generate 10,000 posterior samples after discarding the first 1,000 samples
as burn-in. Trace plots suggest that the posterior sampling converges well.
The proposed method has three main components: the family-wise likelihood to handle
missing genotypes, the ACJ likelihood to correct the ascertainment bias, and the frailty to
capture the family-specific random effects. To evaluate the effects of these three components,
we compare our approach with alternative approaches, under which there is (1) no missing
genotype, (2) no ascertainment bias correction, and (3) no frailty.
Table 2 shows absolute biases and standard deviations of estimates under different ap-
proaches. For the baseline hazard λ0,k(t), bias and standard deviation are numerically in-
tegrated over t. We can see that the estimates without ascertainment bias correction are
severely biased, especially for β2 and λ0,2(t), showing the importance of performing the as-
certainment bias correction. In addition, the estimates with frailty tend to have smaller
biases than those assuming no frailty. Lastly, the efficiency loss due to missing genotypes
is generally small, suggesting that the family-wise likelihood efficiently utilizes the observed
data.
5 Application
We apply the proposed methodology to analyze the LFS data. We consider three types of
LFS-related cancers (K = 3): breast cancer (k = 1), sarcoma (k = 2), and other cancers
(k = 3). Because the individuals with breast cancer in the LFS data are all female (Table
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No bias correction Bias correction
Genotype No fraility Frailty No fraility Frailty
β1
No missing 1.1968 (.3608) 0.7818 (.3385) 1.0667 (.3633) 0.4905 (.3420)
Missing 1.4363 (.4117) 1.2627 (.3421) 1.2824 (.4120) 0.8681 (.3942)
β2
No missing 5.5993 (.1973) 4.7515 (.2051) 0.8659 (.3220) 0.2347 (.4627)
Missing 5.7480 (.2225) 5.4368 (.2267) 1.2012 (.3016) 0.4764 (.3293)
λ0,1(t)
No missing 0.0227 (.0366) 0.0194 (.0409) 0.0190 (.0394) 0.0116 (.0479)
Missing 0.0184 (.0374) 0.0167 (.0398) 0.0166 (.0395) 0.0123 (.0449)
λ0,2(t)
No missing 0.1025 (.0505) 0.0914 (.0518) 0.0004 (.0004) 0.0043 (.0038)
Missing 0.1340 (.0641) 0.1116 (.0540) 0.0010 (.0008) 0.0053 (.0045)
Table 2: Absolute biases and standard deviations (in parentheses) of estimates based on 100
simulations.
1), we impose the following constraint on the hazard of developing breast cancer:
λ1(t|G,X) =
 0, for X = 0 (male),λ0,1(t)ξ1 exp{βG,1G}, for X = 1 (female), (18)
while other types of cancer (k = 2, 3) are assumed to follow the model of the form (5).
There is only one baseline covariate available in the LFS database (i.e., gender), however
our method can readily accommodate more covariates. We ignore all cancers that occurred
after 75 years of age and treat them as censored at age 75, since cancers diagnosed after 75
years of age are clinically irrelevant for estimating the penetrance of LFS.
5.1 Model Parameter Estimates
Posterior estimates for the regression coefficients βk and the inverse of the frailty variances
νk, k = 1, 2, 3 are reported in Table 3. Genotype has a strong effect on the incidence of all
cancer types, with TP53 mutation carriers being more likely to have cancers. Gender also
plays a significant role in sarcoma and other cancers. The regression coefficient of gender is
negative, suggesting that males in this population are more likely to develop sarcoma and
other cancers than females.
The estimates of νks are quite large, which suggests that after accounting for the pedigree
structure through the family-wise likelihood, within-family correlations are not very strong
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in this particular dataset. To check this, we compared the penetrance estimates obtained
from our model to those from the model that does not include frailty and found them to
be quite similar (see Supplementary Materials Section D.3). Although the model without
frailty may be preferred in practice due to its parsimony, we present the results of the frailty
model to emphasize that our approach allows for further flexibility; the results are nearly
identical in terms of the penetrance estimates.
Table 3: Posterior estimates of regression coefficients β and inverse variances of the frailty
ν.
Cancer Parameter Mean SD 2.5% 97.5%
Breast Genotype 3.560 0.516 2.541 4.544
(Frailty Var)−1 6.126 1.850 3.185 10.347
Sarcoma Genotype 2.464 0.895 0.675 4.182
Female -3.677 1.077 -6.176 -1.902
Interaction 0.971 0.548 -0.110 2.040
(Frailty Var)−1 6.574 1.990 3.490 11.227
Others Genotype 1.576 0.769 0.072 3.072
Female -0.993 0.186 -1.366 -0.647
Interaction 0.559 0.574 -0.620 1.628
(Frailty Var)−1 7.148 2.001 3.986 11.857
Figure 2 depicts the posterior estimates of the cumulative baseline hazard. Age has
stronger effects on breast and other cancers than on sarcoma. The cumulative baseline
hazards of breast and other cancers increase exponentially with age, while that of sarcoma
increases approximately linearly with age. We observe that the uncertainty of the sarcoma
baseline hazard estimate is much larger than those of the others. This is because the ascer-
tainment bias is generated from the probands with sarcoma, which makes the ascertainment-
bias-corrected likelihood (14) more sensitive to the parameters directly related to sarcoma.
5.2 Age-at-onset Penetrance
The first three panels (a)–(c) of Figure 3 depict the estimated age-at-onset penetrances,
qk(t|G,X), k = 1, · · · , 3, respectively, for breast cancer, sarcoma, and other cancers. It is not
surprising that the TP53 mutation carriers (G = 1) have higher risk of developing cancer
than the non-carriers (G = 0), regardless of cancer type. The patterns of cancer-specific
penetrance are quite different across cancer types, which justifies the proposed cancer-specific
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Figure 2: Posterior estimates of the cancer-specific cumulative baseline hazard functions for
breast cancer (a), sarcroma (b) and other cancers (c). Dashed lines indicate 95% credible
band of the estimates.
approach. It is of clinical interest that there is a sizable chance that the female TP53
mutation carrier will develop breast cancer before 20 years of age, which is rarely seen in
females with BRCA1 and BRCA2 mutations (two well-known susceptibility gene mutations
for breast cancer) (Berry et al.; 2002). This suggests that early-onset breast cancer is an
important feature of TP53 mutation. We also find that non-carriers have very low probability
of developing sarcoma, although the data contain many cases of sarcoma in non-carriers due
to the use of individuals with sarcoma as probands for collecting the samples (see Table
1). In contrast, ignoring the ascertainment bias leads to substantially biased estimates, see
Supplementary Materials Section D.2 for the comparison between our estimates and the
estimates without performing ascertainment bias correction.
Figure 3, panel (d) shows the overall age-at-onset penetrance obtained by stacking three
cancer-specific penetrances, i.e., q(t|G,X) = ∑3k=1 qk(t|G,X). The overall age-at-onset pen-
etrance quantifies the probability of having any type of cancer by a certain age for carriers
of TP53 mutations. Among the non-carriers, females have lower cancer risk than males;
whereas the female mutation carrier has higher risk than the male mutation carrier due to
the excessively high risk of the female carrier developing breast cancer. Overall, TP53 muta-
tion carriers have very high lifetime risk of developing cancer, demonstrating the importance
of the accurate detection of TP53 germline mutations.
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Figure 3: Cancer-specific age-at-onset penetrances qk(t|G,X), k = 1, 2, 3, are depicted in
(a)–(c), and the overall cancer penetrance q(t|G,X) is given in (d). Shaded areas denote the
95% credible bands.
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5.3 Personalized Risk Prediction
An important application of our analysis results and estimate of age-at-onset penetrance
qk(t|G,X) is to provide a personalized risk prediction for future subjects who are at risk
of developing LFS-related cancers. Our prediction method has two important advantages.
First, it allows us to incorporate the subject’s family cancer history to make more accurate
risk prediction. Second, it is capable to make risk prediction for a subject without knowing
his/her genotype. This is desirable because in practice, genetic test is often of a great
financial and psychological burden for patients. Making risk prediction without performing
a genetic test allows us to quickly detect individuals with high risk of LFS and provide
prompt and proper clinical treatments during an early stage of disease, which is particularly
important in the management of rare diseases such as LFS. Specifically, given a family’s
cancer history Hi and covariates Xi, the risk that the jth individual in the ith family will
develop the kth type of cancer by age t, Rijk(t|Hi,Xi), is predicted by
Rijk(t|Hi,Xi) = Pr(Tij ≤ t,Dij = k|Hi,Xi) =
∑
Gij∈{0,1}
Pr(Gij|Hi,Xi)qk(t|Gij, Xij). (19)
That is, the predicted cancer-specific risk is a weighted average of the cancer-specific pen-
etrance qk(t|Gij, Xij). The weight Pr(Gij|Hi,Xi), also known as carrier probability, is the
likelihood that the subject carries a specific genotype Gij, given his/her family cancer history
Hi and covariates Xi. It can be routinely calculated using Bayes’ rule and Mendelian laws
of inheritance, see Supplementary Materials Section B for details. As we assume that the
subject’s genotype Gij is unknown, the calculation of the risk in (19) is marginalized over
all possible values of Gij.
To illustrate the utility of our method, consider two hypothetical families that have
similar pedigree structures, but different genotypes and cancer histories, as shown in Figure
4. Family 1 does not carry the mutated allele and has three cases of cancer (two breast
and one other cancers), and family 2 carries the mutated allele with four cases of cancer
(one breast, two sarcoma and one other cancers). As mothers (the second generation) in
both families had breast cancer, it is of great interest to predict the cancer risk for their
daughters, referred to as counselees 1 and 2 in Figure 4. We consider two situations: the
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(a) Family 1 (b) Family 2
Figure 4: Pedigrees of two families, where square and circle represent male and female
subjects, respectively. The symbol is partitioned into four sections, which represent statuses
of genotype (topleft), breast cancer (bottom left), sarcoma (bottom right), and other cancers
(topright). Filled sections represent that the subject carries a mutated allele or had a certain
type of cancer. The number in the parentheses is subject’s current age.
genotypes of the counselees are known or unknown. Specifically, when the genotypes of the
counselees and their family are unknown, we predict the cancer risk for the counselees based
on equation (19) with the cancer-specific penetrance estimated from the LFS data. When
the genotypes of the conselees are known (i.e., conselee 1 is non-carrier and 2 is carrier), the
risk prediction is straightforward and the cancer risk of the conselees is simply the estimated
cancer-specific penetrances qk(t|G,X). Figure 5 shows the predicted cancer-specific risks of
the counselees when their genotypes are known and unknown. Clearly, counselee 2 has a
substantially higher risk of developing cancer than the counselee 1. Based on this result,
we may recommend more frequent cancer screening for counselee 2. We note that counselee
2 has a very low risk of developing sarcoma although her family has two cases of sarcoma.
This is because, as shown in Figure 3(b), the penetrance for sarcoma is high in male, but
very low in female.
5.4 External and Interval Validation
As an external validation, we compare our estimates of non-carrier penetrance to those pro-
vided by the National Cancer Institute on the basis of the Surveillance, Epidemiology, and
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Figure 5: Predicted cancer-specific risk for counselees 1 and 2 when their genotypes G are
known or unknown.
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End Results (SEER) data. SEER is an authoritative source of information on cancer inci-
dence and survival in the United States. It currently collects and publishes cancer incidence
and survival data from population-based cancer registries that cover approximately 28% of
the US population. SEER is the only comprehensive source of population-based information
in the United States that includes the stage of cancer at the time of diagnosis and patient
survival data. The SEER estimate can be regarded as a reference estimate for the normal
US population (i.e., non-carrier). More details regarding SEER estimates can be found at
http://seer.cancer.gov.
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Figure 6: External validation of the estimated penetrance for non-carrier (solid lines) through
comparison to the SEER estimates (dashed lines). Shaded areas represent the 95% credible
bands. For panel (c), the dotted line indicates the estimate based on the Cox model.
Figure 6 compares the penetrance of breast cancer, sarcoma, and all cancers for non-
carriers to the most recent SEER estimates based on the data collected from 2008 to 2010.
We can see that the estimates of non-carrier penetrance are generally consistent with the
corresponding SEER estimates, suggesting that the proposed methodology performs well.
For the purpose of comparison, we also show the estimate of the overall cancer penetrance
based on the conventional Cox model for the time to cancer diagnosis using subjects with
known genotypes. As shown in Figure 6, panel (c), the estimate of the overall cancer risk
based on the proposed method is much closer to the SEER estimate than the estimate based
on the Cox model.
We conduct internal validation through cross-validation. First, we randomly split the
data (i.e., 186 families) into two halves. We use one half (i.e., 93 families) as the training fami-
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Figure 7: The ROC curve for the cancer-specific risk prediction at age 50. Values in the
parentheses are standard deviations of the AUC. Shaded areas represent pointwise 95%
variations of the ROC curves from different random partitions.
lies {(Htri ,Xtri ,Gtrobs,i), i = 1, · · · , 93}, and the other half as the test families, {(Htri′ ,Xtri′ ,Gtrobs,i′),
i′ = 1, · · · , 93}. Next, we estimate the cancer-specific penetrance using the training families,
denoted by qˆtrk (t|G,X). Based on this estimate and equation (19), we predict the cancer-
specific risk at a given age tc for subjects in the test families, i.e., Ri′jk(tc|Htsi′ ,Xtsi′ ). Given
a certain risk cutoff ψ, we predict that a subject will have kth type of cancers by age tc
if Ri′jk(tc|Htsi′ ,Xtsi′ ) > ψ. By varying the risk cutoff ψ and comparing the predicted cancer
status with the actually observed cancer status of the test families, we obtain the receiver
operating characteristic (ROC) curves of our cancer risk prediction model. Figure 7 depicts
the ROC curve of the predicted risk of the test family members at age 50 years for different
cancer types. These results show reasonable performance, with the area under the ROC
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curves (AUC) being 0.773, 0.791 and 0.755 for predicting breast cancer, sarcoma and other
cancers, respectively. For breast cancer, the ROC curves are generated from the females
only since we assume no breast cancer for the males. We also consider the ROC curves for
other caner-onset ages, tc = 30, 40, and 60 years. The results are generally similar to that of
tc = 50 years, see Supplementary Materials Section F.
5.5 Model Comparison
Due to the complicated structure of the LFS data (e.g., family structure, missing genotype,
ascertainment bias and competing risks), standard model diagnosis tools for survival models,
such as residuals (Schoenfeld; 1982; Therneau et al.; 1990) and chi-squared goodness-of-fit
tests (Hjort; 1990; Hollander and Pena; 1992; Li and Doss; 1993), are not applicable here.
We assess the adequacy of the proposed model through model comparison. We consider
four alternative models. The first three models are obtained by replacing the Bayesian non-
parametric baseline hazard model with three parametric models: the exponential, Weibull,
and piecewise-constant models, respectively. For the piecewise-constant model, we use four
equally spaced knots to obtain five partitions. The fourth model is obtained by removing the
frailty ξi,k from the competing risk model (5). We use two metrics to measure the goodness
of fit of the models: the deviance information criterion (DIC) and conditional predictive
ordinate (CPO, Ibrahim et al.; 2005). The DIC measures the overall goodness of fit of a
model and the CPO measures the predictive ability of a model. The CPO for the ith family
is defined as
CPOi = Pr(Hi|D(−i),Gi,obs,Xi, ξi,Ai) =
[
E
(
1
Pr(Hi|Gi,obs,Xi, ξi,θ,Ai)
)]−1
(20)
where D(−i) = (H(−i),G(−i),obs,X(−i)) represents the data with the ith family data deleted,
and the expectation is made with respect to the posterior distribution of θ. The Monte
Carlo approximation of (20) is given by
ĈPOi =
[
1
L
L∑
`=1
1
Pr(Hi|Gi,obs,Xi, ξˆi,(l), θˆ(`),Ai)
]−1
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where ξˆi,(`) and θˆ(`) denote posterior samples from the `th MCMC iteration, ` = 1, · · · , L.
Table 4 shows the DIC and
∑I
i=1 log ĈPOi, known as the pseudo-marginal log-likelihood
(PsML), for the different models. Smaller DIC values and larger PsML values suggest a
better model. The proposed model based on Bernstein polynomials provides better goodness
of fit and predictive ability than the models with exponential, Weibull, or piecewise-constant
baseline hazards. The difference between the proposed model and the model without frailty
is small, suggesting a weak within-family correlation. This is concordant with our finding
that ν estimates are large (see Table 3). For the purpose of comparison, we also perform the
analysis based only on the subset of the data for whom the genotypes are observed, and the
analysis without ascertainment bias correction. The estimates of cancer-specific penetrance
under different approaches are provided in Supplementary Materials (Section D).
Baseline Frailty
Model hazard included DIC . PsML
1 Exponential Yes 3273.7 −1657.120
2 Weibull Yes 3020.2 −1512.252
3 Piecewise Yes 3010.3 −1513.405
4 Bernstein. No 2989.3 −1499.735
Proposed Bernstein Yes 2983.7 −1499.689
Table 4: Comparison of the proposed model with four alternative models.
5.6 Sensitivity Analysis
We consider nine different combinations of priors for γm,k and νk: three different priors for
γm,k including flat prior, Gamma(0.01, 0.01), and Gamma(1, 1); and three priors for νk ∼
Gamma(0.01, 0.01), Gamma(0.1, 0.1) and Gamma(1, 1). The results (see Supplementary
Materials Section E) show that the estimates are not particularly sensitive to the choice of
priors.
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6 Discussion
In the LFS study, estimating cancer-specific penetrance is not trivial under the presence of
competing risks, but is essential for providing better treatment that is personalized to the
patient’s needs. We developed a cancer-specific age-at-onset penetrance model and proposed
an associated Bayesian estimation scheme. The proposed method can incorporate all the
family histories in the estimation by exploiting the family-wise likelihood. We also corrected
the ascertainment bias, which is an important task in family data studies of rare diseases.
One detriment when modeling the cause-specific hazard in competing risk analysis is
that covariate effects on the subdistribution (i.e., cancer-specific penetrance) are not inter-
pretable. As an alternative, Fine and Gray (1999) proposed a proportional model for the
subdistribution that enables us to directly assess the covariate effects on the corresponding
cancer-specific penetrance. It is not difficult to equivalently rewrite the individual likeli-
hood in terms of the cancer-specific penetrance and the associated derivative (Maller and
Zhou; 2002). The family-wise likelihood approach can be similarly applied to this alternative
modeling approach.
In the LFS study, a patient can have multiple primary cancers during his or her lifetime.
In the current approach, we consider only the first cancer that occurred and discard all the
subsequent cancer history. In order to incorporate a longitudinal history that may involve
multiple cancers, our approach can be extended to the so-called multi-state model (Putter
et al.; 2007) to recurrently observe multiple failures. In theory, the multi-state model can
be regarded as an extended version of the competing risk model. However, it is practically
challenging to collect data for a sufficient number of subjects who have multiple primary
cancers in order to attain an appropriate level of estimation accuracy.
Supplementary Material
Supplementary Material includes an illustrative example of the peeling algorithm, a descrip-
tion of the carrier probability estimation based on family cancer history, additional simu-
lation results for different baseline hazard models, penetrance of LFS estimated by various
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competing methods, prior sensitivity analysis, and cross-validated ROC curves at different
ages.
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